Ming Lu

Address:

703 Galliton Ln, Towson, MD 21204

Phone:

(410)3372733

VIN:

4T1BE46K17U110032

Make:

TOYOTA

Model:

CAMRY

Year:

2007

US Patent:

6362011, Mar 26, 2002

Filed:

Feb 2, 1999

Appl. No.:

09/243215

Inventors:

Richard J. Massey - Rockville MD
Mark T. Martin - Bethesda MD
Liwen Dong - Rockville MD
Ming Lu - Lanham MD
Alan Fischer - Cambridge MA
Fabian Jameison - Gaithersburg MD
Pam Liang - Rockville MD
Robert Hoch - Hensonville NY
Jonathan K. Leland - Silver Spring MD

Assignee:

Meso Scale Technologies, LLC - Gaithersburg MD

International Classification:

G01N 33551

US Classification:

436526, 435 6, 435 74, 435 75, 435 792, 435 793, 435 794, 435 24, 435 26, 435176, 435182, 436524, 436535, 436806, 5303911, 5303913, 5303915

Abstract:

Graphitic nanotubes, which include tubular fullerenes (commonly called âbuckytubesâ) and fibrils, which are functionalized by chemical substitution, are used as solid supports in electrogenerated chemiluminescence assays. The graphitic nanotubes are chemically modified with functional group biomolecules prior to use in an assay. Association of electrochemiluminescent ruthenium complexes with the functional group biomolecule-modified nanotubes permits detection of molecules including nucleic acids, antigens, enzymes, and enzyme substrates by multiple formats.

US Patent:

7052861, May 30, 2006

Filed:

Dec 5, 2001

Appl. No.:

10/007526

Inventors:

Richard J. Massey - Rockville MD, US
Mark T. Martin - N. Bethesda MD, US
Liwen Dong - Rockville MD, US
Ming Lu - Lanham MD, US
Alan Fischer - Cambridge MA, US
Fabian Jameison - Gaithersburg MD, US
Pam Liang - Baltimore MD, US
Robert Hoch - Hensonville NY, US
Jonathan K. Leland - Silver Spring MD, US

Assignee:

Meso Scale Technologies, LLC. - Gaithersburg MD

International Classification:

G01N 33/573
G01N 33/533
G01N 33/553
G01N 21/76
C12Q 1/32

US Classification:

435 74, 435 26, 435968, 436172, 436524, 436526, 436546, 436805

Abstract:

Graphitic nanotubes, which include tubular fullerenes (commonly called “buckytubes”) and fibrils, which are functionalized by chemical substitution, are used as solid supports in electrogenerated chemiluminescence assays. The graphitic nanotubes are chemically modified with functional group biomolecules prior to use in an assay. Association of electrochemiluminescent ruthenium complexes with the functional group biomolecule-modified nanotubes permits detection of molecules including nucleic acids, antigens, enzymes, and enzyme substrates by multiple formats.

US Patent:

20040202603, Oct 14, 2004

Filed:

Apr 30, 2004

Appl. No.:

10/837125

Inventors:

Alan Fischer - Cambridge MA, US
Robert Hoch - Hensonville NY, US
David Moy - Winchester MA, US
Ming Lu - Lanham MD, US
Mark Martin - N. Bethesda MD, US
Chun Niu - Somerville MA, US
Naoya Ogata - Tokyo, JP
Howard Tennent - Kennett Square PA, US
Liwen Dong - Rockville MD, US
Ji Sun - Potomac MD, US
Larry Helms - Germantown MD, US
Fabian Jameison - Gaithersburg MD, US
Pam Liang - Alhambra CA, US
David Simpson - N. Bethesda MD, US

Assignee:

Hyperion Catalysis International, Inc.

International Classification:

D01F009/12
C07C063/333

US Classification:

423/447200, 562/492000, 564/426000

Abstract:

Graphitic nanotubes, which includes tubular fullerenes (commonly called “buckytubes”) and fibrils, which are functionalized by chemical substitution or by adsorption of functional moieties. More specifically the invention relates to graphitic nanotubes which are uniformly or non-uniformly substituted with chemical moieties or upon which certain cyclic compounds are adsorbed and to complex structures comprised of such functionalized nanotubes linked to one another. The invention also relates to methods for introducing functional groups onto the surface of such nanotubes. The invention further relates to uses for functionalized nanotubes.

US Patent:

20060160246, Jul 20, 2006

Filed:

Mar 20, 2006

Appl. No.:

11/385277

Inventors:

Richard Massey - Rockville MD, US
Mark Martin - N. Bethesda MD, US
Liwen Dong - Rockville MD, US
Ming Lu - Lanham MD, US
Alan Fischer - Cambridge MA, US
Fabian Jameison - Gaithersburg MD, US
Pam Liang - Baltimore MD, US
Robert Hoch - Hensonville NY, US
Jonathan Leland - Silver Spring MD, US

International Classification:

G01N 33/543
C12M 1/34

US Classification:

436518000, 435287200, 977746000

Abstract:

Graphitic nanotubes, which include tubular fullerenes (commonly called “buckytubes”) and fibrils, which are functionalized by chemical substitution, are used as solid supports in electrogenerated chemiluminescence assays. The graphitic nanotubes are chemically modified with functional group biomolecules prior to use in an assay. Association of electrochemiluminescent ruthenium complexes with the functional group biomolecule-modified nanotubes permits detection of molecules including nucleic acids, antigens, enzymes, and enzyme substrates by multiple formats.

US Patent:

20080261243, Oct 23, 2008

Filed:

Oct 6, 2005

Appl. No.:

11/575811

Inventors:

Robert M. Lorence - Bethesda MD, US
Ming Lu - Potomac MD, US

Assignee:

WELLSTAT BIOLOGICS CORPORATION - Gaitherbsurg MD

International Classification:

G01N 33/574

US Classification:

435 723

Abstract:

The expression of Her-2/neu protein on circulating cancer cells in a blood sample is detected by isolating the cancer cells from the blood sample and then performing on the isolated cancer cells a sensitive Her-2/neu immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN).

US Patent:

20090291920, Nov 26, 2009

Filed:

Apr 18, 2007

Appl. No.:

12/296458

Inventors:

Ming Lu - Potomac MD, US
Robert M. Lorence - Bethesda MD, US

Assignee:

WELLSTAT BIOLOGICS CORPORATION - Gaithersburg MD

International Classification:

A61K 31/566
C12Q 1/02
A61K 31/565
A61K 31/4353
A61K 31/4196

US Classification:

514 77, 435 29, 514182, 514300, 514383

Abstract:

The expression of a steroid receptor from circulating carcinoma cells in a blood sample is detected by isolating the carcinoma cells from the blood sample, making an extract from the isolated carcinoma cells and then performing on the extract a sensitive immunoassay capable of detecting the carcinoma cell-associated steroid receptor. A positive result indicates the presence of the steroid receptor in the carcinoma cells. This method can be used to identify cancer patients who are likely to benefit from treatment with an endocrine therapeutic agent.

US Patent:

20100120072, May 13, 2010

Filed:

Apr 15, 2008

Appl. No.:

12/593160

Inventors:

Robert M. Lorence - Bethesda MD, US
Ming Lu - Potomac MD, US

Assignee:

WELLSTAT BIOLOGICS CORPORATION - Gaithersburg MD

International Classification:

G01N 33/574

US Classification:

435 723

Abstract:

The expression of Her-2/neu protein on circulating cancer cells in a sample of blood or peripheral blood mononuclear cells (PBMCs) is detected by performing a sensitive Her-2/neu immunoassay. There is no need to isolate the cancer cells before performing the immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN), lapatinib, CP-724,714, NKI-272, and BMS-599626

US Patent:

20110070598, Mar 24, 2011

Filed:

Feb 18, 2010

Appl. No.:

12/708159

Inventors:

Robert M. Lorence - Bethesda MD, US
Ming Lu - Potomac MD, US

Assignee:

WELLSTAT BIOLOGICS CORPORATION - Gaithersburg MD

International Classification:

G01N 33/574
G01N 33/577

US Classification:

435 723

Abstract:

The expression of Her-2/neu protein on circulating cancer cells in a blood sample is detected by isolating the cancer cells from the blood sample and then performing on the isolated cancer cells a sensitive Her-2/neu immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN).